The National Medical Products Administration has approved the marketing of Demozia maca injection
March 30, 2026
Source: drugdu
32
Recently, the National Medical Products Administration (NMPA) approved the marketing of Demozia macaase injection (trade name: Easily) submitted by GlaxoSmithKline Trading Services Limited. This product is indicated for maintenance treatment of severe eosinophilic asthma in adults and adolescents aged 12 years and older. The approval of this product provides a new treatment option for these patients.
Source: Official WeChat account of the National Medical Products Administration
https://mp.weixin.qq.com/s/_3PsNe601R7lhzvh1cSn2w
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Say goodbye to lifelong IV drips! FDA approves first in vivo gene therapy for infantile Pompe disease March 30, 2026
- Recombinant type A botulinum toxin for injection successfully approved for marketing March 30, 2026
- providing new options for patients with psoriasis and hidradenitis suppurativa. March 30, 2026
- GE Healthcare’s Photon-Counting CT System Approved by FDA March 30, 2026
- 350 Million Yuan! Diabetes Pulse Therapy Startup Completes Another Round of Financing March 30, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
